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Peripheral blood ly mphocy tes isolated from 19 pa-
tients with progressive systemic sclerosis (7 with diffuse 
scleroderma and 12 with CREST syndrome) and from 
19 healthy control individuals were tested in a lympho-
cyte-induced angiogenesis assay . The cells were injected 
intradermally into x-ray-immunosuppressed mice and 
their capability to induce new blood vessel formation 
was assessed by morphologic criteria. The lymphocytes 
derived from patients with systemic scleroderma 
showed a significant decrease in angiogeneic capability 
compared with controls. No significant difference in this 
capability was found between patients with diffuse scle-
roderma and those with CREST sy ndrome. The decrease 
in the angiogeneic capability of lymphocytes reflects a 
depression in cell-mediated immunity and might be rel-
evant to the capillary loss observed in systemic sclero-
derma. 
Scleroderma is a systemic connective t issue disorder cha r-
acterized by in fl ammatory, fibrotic, and degenerative changes 
[1). Diffe rent mec hanisms have been proposed for the patho-
ge nesis of t his disease, suggest ing t he involvement of fibro-
blasts, blood vessels, a nd t he immune system. Defects in fibro-
blast function resul t ing in excessive co llage n, fibronect.in , a nd 
glycosaminoglycan synthesis and accumulation h ave been doc-
umented [2- 5]. In t he serum of scleroderma pat1ents a m1togen 
has been found [6) t hat is select ive for fibroblasts [7). The 
increase in fibroblast proliferation and in matrix sy nt hesis may 
be dependent on mediators released from mononuclea r cell s [8-
10), which become activated during t he immune resp onse . 
Abnormal immune react ivity has been shown to occur 111 sys-
temic sclerode rma as manifested by the posit ive reaction to 
co ll age n a nd skin extracts [11 ,12, *) a nd the presence of va rious 
a n t ibodies directed against a va riety of self-constituents [13). 
A decrease in reactivity to some mitogens a nd an tmmuno-
regulatory T -cell disba lance were a lso observed [14- 18]. 
In addi t ion to t he immunologic abnorma li t ies, blood vesse l 
a lte rat ions were found to be an importa n t facto r in the patho-
ge nesis of systemic scleroderma . The vascula r involvements 
include Ray naud 's phenomenon, capilla ry abnorm ali ties with 
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capilla ry loss, morphologic changes in sma ll ar teries and a rter-
ioles, a nd t he presence of serum cytotoxic facto rs that damage 
the vascul a r endothelium [3,19- 24). 
Immune eve nts leadin g to vascula r lesions a re observed in 
many di seases. It is a lso poss ible t hat t he interre lation of 
vascula r and immunologic phenomena may occur in systemic 
sc leroderma. T o investigate t his, we have employed a so-called 
lymphocyte- induced angiogenesis (LIA) assay t hat a llows t he 
s imul ta neous examination of both t he immunocompetence of 
lymphoid ce lls a nd t heir effect on microvasculature. The LIA 
assay, int roduced by Auerbach and collaborators [25-27) was 
s hown to be a rapid, se ns it ive, and quan itative test fo r cell -
mediated immunity (CMI ) in vivo. In t his assay an in t radermal 
injection of incompatible lymphocytes into a mouse evokes a 
local graft-vs- host reaction resul t ing in new blood vessel for-
mation at t he injection site. The number of newly for med blood 
vesse ls is depe ndent on t he dose, origin , and immunocompe-
tence of t he injected cells and on the degree of incompatibility 
betwee n lymphocyte donor and recipien t . T his assay was s hown 
to be sui tab le for testing t he immunocompetence (expressed as 
t he a ngioge neic capabi lity) o f normal huma n peripheral blood 
lymphocytes (PBL ) [28 ]. 
The presen t study was undertaken to assess t he capability of 
PBL from patients wit h systemic scle roderma (both di ffuse 
sc leroderma and CREST syndrome) to induce new blood vessel 
fo rmation. For t hi s purpose an LIA assay in mice was used. 
MATERIALS AND METHODS 
Patients 
Studies were performed on 19 patients with systemic scleroderma; 
the group included 7 patients with diffuse scleroderma and 12 with 
CREST syndrome, class ified according to Rodnan [1]. Patients, rang-
ing in age from 24-GO years (mean 47.1), had suffered 0.5- 4 years (mean 
1.8) in the group of diffuse scleroderma and 3-27 years (mea n 11.8) in 
the CREST group (Table 1) . 
Labora tory Protocol 
The patients were evaluated according to a standard cl inical and 
laborato ry protocol. 
Cri te ria of organ involvement in patients with systemic sclerosis 
we re the following: 
Lungs: Radiologic changes and abnormal pulmonary funct ion tests, 
class ified by vita l capacity, to tal lung capacity, and residual volume 
Heart: ECG changes 
Kidneys: Creatinine clearance, urinalysis 
Muscle: Electromyography, studies of muscle enzymes (creatinphos-
phokinase, aldolase, t ransaminases, in some cases muscle biopsy) 
Antinuclea r antibodies (ANA) were measured by indirect immuno-
f1uorescence test. according to Beutner et a! [29], with the use of 
different substrates: rat liver, monkey esophagus and, fo r cent romere 
antibodies determi nation, HEp 2 cells [13]. CMJ was measured by in 
vit ro and in vivo tests. 
E rosettes: PBL were isolated on Ficoll-Isopaque gradient and washed 
3 t imes wi th Hanks' medium at 400 g for 5 min. Equal volumes (0.2 
ml ) of lymphocyte suspension (4 X 106/ ml), 0.52 washed sheep eryth-
rocytes (SRBC), and heart- inactivated SRBC-absorbed fetal calf serum 
were mi xed. T he lymphocyte:erythrocyte ratio was 1:10. The mixture 
was incubated 45 min at 3TC, centrifuged 5 min at 200 g , and kept 
overnight at 4•c. Each test was run in duplicate. Normal mean 68.4 ± 
5.4, range 58.5- 80.0. 
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TABLE I. Clinical and labora tory data of patients with systemic sclerosis 
Duration (years) Orga n invo lvement 
Patient/Sex/ Age Capil · ANA CMI ' Trea t -Raynaud 's lndu- Arthral - Central la roscopy" titer Calcinos is Esophagus Lungs Heart l<idney Muscles ment < phenomenon ration gia skin 
Diffuse scleroderma 
1. E.P . F 44 0.5 1 1 + R, S 0 ! no 
2. J .M. F 34 4 1 1 + + + R, S 160 ! no 
3. U.J . F 24 3 2 2 + + R 160 N no 
4. K. S. F 51 6 2 5 + + + R, S 640 !fN no 
5. J .I. M 55 1 0.5 0.5 + + + + + + s 0 ! yes 
6. B.C. F 27 5 4 3 + + + + R, S 40 N yes 
7. U.B. F 43 4 0.5 3 + + R,S 640 N no 
CREST syndrome 
1. z.o. F 59 43 27" 25 + + + + s 20 nd no 
2. L.T. F 60 30 27" 16 + + + + + R,S 40 nd no 
3. M.L. F 45 19 9" 9 + + + R, S 320 !fN no 
4. e.G. F 42 16 7' 10 + + + R,S so1 N no 
5. J.S. F 56 28 19 + + R, S 0 nd no 
6. J .M. F 42 12 3' 4 + + + R 2650 N no 
7. K.M . F 51 25 10" no + + R, S 640 N no 
8. W.R. F 49 29 27 27 + + + + R, S 160 N yes 
9. J.M. F 41 25 10' 6 + + + R, S 320 N yes 
10. T .K. F 56 25 17" 17 + + + s 160 N no 
11. J.M . F 57 28 4" 19 + + + + s 40 N yes 
12. J .L. F 59 19 11 ' no + ± R, S 40 N no 
" R = Gigan t ic, uneven loops with enla rged centra l port ion , cha racteri stic of Raynaud's phenomenon; S = loss of capilla ries, characte ristic of 
systemic scleroderma [22,23 ]. 
" ! = Decrease, N = normal. 
·· T reatment included cardiovascula r drugs. Prednisone and cyclophosphamide were administe red only to patient B.C. wi th diffuse scle roderma 
who had concurrent renal amyloidosis. ' 
" Indu rations were s light and limited to t he fingers and/or hands, with sclerodactyly. 
,. Indurative edema of the fin gers, no sclerodactyly. 
r Ant icentromere ant ibodies. 
Lymphocyte transformation.: PBL separated on a Ficoll -lsopaque 
gradient were washed twice with cold phosphate-buffered saline and 
diluted with minimal essent ia l medium (containing 5% of fetal ca lf 
serum , 2 mM/ ml glutamine, lOOU/ml penicillin, and 100 f.L g/ml strep-
tomycin) to a density of 1 X 10" cells/mi. Two separate cultures were 
set up in duplicate in 2-ml volumes: (1 ) without the mitogen and (2) 
wi th phytohemagglut inin (PHA), 20 f.Lg/ml. The percentage of blast 
ce lls afte r incubation at 3TC was determined in 4-day cultures. Normal 
percent of blast cells: mean 69.3 ± 7.5, range 55- 84. 
S ensitization. to dinitrochloroben.zen.e (DNCB): P atients were sensi-
t ized wi t h 2000 f.L g DNCB on a 3 cm2 a rea of skin and challenged after 
14 days wi th decreasing doses of DNCB: 100, 50, 25, and 12.5 JJ.g. The 
test s ite was inspected a fter 48 h and the result was considered positive 
when at least one- half of t he test area was erythematous. 
CM I was considered as decreased if 2 in vi t ro tests and/or DNCB 
sensitizat ion test were abnormal. Clinical and laboratory data of pa-
t ients are shown in T able I. The control group included 19 sex- and 
age- matched healthy subjec ts; 16 were blood donors (age range 19- 40 
years) and 3 had just recovered from ulcus cruris (age range 55-63 
years) and had not rece ived any systemic t herapy at a ll. 
CelL~ 
Peripheral blood mononuclear cells were isolated by the method of 
Boyum [30] with s light modifi cat ion [28]. Brie f1y , 10- 15 ml of hepar in-
ized blood samples were dilu ted 1:1 wi t h phosphate buffered saline 
(P BS), laye red over Ficoli -Uropoline mixture (at room temperature), 
and cent rifuged a t 100 g for 11 min. Mononuclear cells were then 
harvested and rinsed 3 times wi t h PBS. Finally, the cells were sus-
pended in T C 199 medium at a concentration of 107 viable ce lls per 1 
ml. The isolated cells consisted of 92- 97% lymphocytes and 3-8% 
monocytes (as ident ified by myeloperoxidase staining). 
Mice 
BALB/c inbred female mice, 4- 5 months old, were used throughout 
the studies. The mice were kept on a standard diet with water ad 
libitum. In order to prevent the rejec tion of human cells, the mice were 
immunosuppressed by a total-body x-ray exposure of 600 R (Miiller 
RT 1100 x-ray apparatus, 100 R per min in a ir, filter A1 1.25 mm, 
irradiation a t 10 rnA, 70 kV). The x-ray irradiation was shown previ -
ously to enhance the angiogeneic reaction in bot h a llo- a nd xenogeneic 
systems [25 ,31]. 
Angiogenesis A ssay 
Two hours after irradiat ion t he mice were anestheti zed wi th chlora l 
hydrate (3.6 mg per 10 g of body weight ), and both f1anks shaved wi t h 
elec tric clippers. The cells to be tested were injected intradermally. 
The required dose of cells was injected in a constant volume of 0.1 ml 
of T C 199 medium per single injection . Each recipient was injected 
with a t least 2 different inocula. Each kind of inoculum was injected 
in different f1ank locations on different recipients. Each mouse has 
received 1- 4 injections, and in each experiment 4- 10 mice were used, 
depending on yield of cells . 
The injection pattern as well as the recipients were coded. After 3 
days t he mice were killed by cervical dislocation , their skin was dis-
sected from the underlying muscles, and its inner surface inspected 
under t he dissecting microscope at 32X magnification using the green 
filter. The location of the injec tion s ite was facilitated when 2- 3 drops 
oftrypan blue (diluted 1:1000) were added to 1 ml of the cell suspension 
prior to the injection. 
All blood vessels directed towa rd the injection s ite were counted 
according to morphologic criteria proposed by Sidky and Auerbach 
[25]. These vessels differed from the background vasculature due to 
their tortuosity a nd bifurcations (Figs 1, 2). All coun t ing was blind and 
performed by the same person (MJK) . 
Specificity of the Angiogeneic Reaction 
T o cont rol t he specificity of the angiogeneic reaction, a group of 
mice was injected int radermally with human lymphocytes, human 
erythrocytes, and murine syngeneic BALB/c splenocytes in a dose of 
10'; ce lls per s ingle injec tion. The angiogeneic reaction was assessed on 
the third day after injection. 
Cell-Dose Dependence of Angiogeneic Reaction 
T o determine the cell-dose dependence of the angiogeneic reaction, 
a group of 8 mice was injected with varying doses of lymphocytes (0.5, 
1.0, 1.5, and 2 X 10" viable cells per single injection) derived from t he 
same heal thy donor. Each mouse was injected twice with each of the 
above doses (total of 8 injections per mouse). 
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FIG l. Strong angiogeneic reaction. To visua lize, t he reaction ves-
sels were fill ed with a solution of India ink supplemented with Triton -
X 100. Site of injection seen as a blac k spot. Numerous to rtuous blood 
vessels wi t h bifurcations. Magnification x 150. 
FI G 2. Normal vasculature of the mouse skin (no injection) . Mag-
nification x 150. 
Comparison. of Angiogen.eic Capability of Lymphocytes from Systemic 
Scleroderma Patients and from Control S ubjects 
In t he experimenta l group, mice were injected with a single dose of 
106 viable cells from at least I patient with systemic scleroderma and 
1 healt hy control subject. The intensity of angiogeneic reaction was 
estimated on the third day after the injections. 
Histologic and Autoradiographic S tudies 
Skin fragments injected previously with lymphocytes were dissected 
a nd processed to obta in semi t hin plastic sections. The 2.0-11m sections 
were stained either with to luidine blue or with Harris hematoxylin for 
48 h. 
Four mice were injected with tritiated thym idine l 11Ci/l g of body 
weight i.p. (spec act of thyntidine = 27 Ci/ mmol, Amersham, England) . 
Semi thin plastic sections from t he skin angiogeneic reactions were 
p rocessed fo r autorad iography, using Kodak ARlO stripping film . After 
processing, the slides were stained with hematoxylin for 48 h. 
RESULTS 
Human periphera l b lood lymphocytes iso lated from hea lt hy 
controls and from patients wi t h sys tem ic scle roderm a disp layed 
a n abili ty to evo ke angiogenesis in x- ray-immunosuppressed 
mice. The a ngioge nesis- inducing capabili ty was specific for 
ly mphocytes only, si nce ne it her human e rythrocytes nor syn -
geneic (BALB/c) lymp hoid ce lls evoked a n giogenesis greate r 
t han background. T he angioge neic reaction evoked by hum a n 
ly mphocytes showed a cell -dose dependence (Table II). 
The intensity of a ngiogeneic reaction evoked by patien ts ' 
lymphocytes, irrespective of scleroderma type and treatme n t, 
was lower t ha n t hat evo ked by control cells. Within t he scle-
roderma group , t here was no diffe rence in a ngiogeneic capabi l-
ity between CREST syndrome a nd diffuse scleroderma. The 
results a re presented in T a ble III. 
TABLE II. A n.giogenesis dependence on. the cell dose injected 
Cell dose (X 106 ) 
0.5 
l.O 
1.5 
2.0 
Angiogenesis 
11.80 ± 0.46 (16) 
13.95 ± 0.66 (16) 
15.95 ± 1.22 ( 16) 
18.70 ± 1.25 (16) 
Angiogenesis evoked in skin of x-ray- irradiated BALB/c mice 3 days 
afte r injection of viable lymphocytes. Angiogenesis is expressed as a 
mean number of newly formed blood vessels per single injection site ± 
SE. In parentheses is t he number of injections. 
TABLE III. Th e angiogeneic capab£/ity of peripheral blood ly mphocytes 
obtamed from. patients with diffuse scleroderma on.d CREST syndrome 
Patient Angiogeneic capab ilit y Angiogeneic capability (controls) 
Diffuse scleroderma 
1. E.P. 10.10 ± 0.48 (26) 13.20 ± 1.1 8 (10) 
2. J.M. 11.75 ± 1.25 ( L2) 13.60 ± 2.02 (10) 
3. U.J. 11.91 ± 1.31 (12) 13.80 ± 0.49 (10) 
4. K.S. 12.20 ± 0.84 (20) 13.30 ± 0.75 (20) 
5. J .l. 12.83 ± 1.50 (8) 16.16 ± 2.89 (8) 
6. B.C. 14 .00 ± 2.34 (15) 12.37 ± 0.68 (8) 
7. U.B. 15.16 ± 1.21 (32) 16.80 ± 1.06 (10) 
Mean 12.56 ± 0.62 14.18 ± 0.62 
CREST 
1. z.o. 10.73 ± 1.20 (15) 12.36 ± 0.60 (1 2) 
2. L.T. 10.75 ± 1.19 (4) 12.00 ± 0.53 (13) 
3. M.L. 10.75 ± 1.09 (4) 14.60 ± 1.54 (1 0) 
4. G.G. 11.60 ± 0.52 (9) 14.10 ± 1.32 (9) 
5. J.S. 12.62 ± 1.66 (10) 15.14 ± 1.07 (10) 
6. J .M. 13.08 ± 1.23 (9) 13.00 ± 0.82 (1 2) 
7. K.M. 12.90 ± 1.09 ( 11) 14.72 ± 0.75 (11) 
8. W.R. 13.72 ± 0.75 (11) 14.00 ± 1.05 (11) 
9. J .M. 13.87 ± 1.32 (10) 17.00 ± 1.25 (7) 
10. T .K. 14.70 ± 1.33 (6) 15.66 ± 0.95 (9) 
11. J.M. 15.50 ± 1.22 (1 2) 16.80 ± 1.32 (I 0) 
12. J.L. 11.54 ± 0.78 (11) 15.45 ± 0.76 (11) 
Mea n 12.65 ± 0.46 14.57 ± 0.46 
Angiogenesis evoked in skin of x-ray irradiated BALB/c mice 3 days 
after injection of 106 viable lymphocytes. Angiogenesis is expressed as 
a mean number of newly fo rmed blood vessels per single injection site 
± SE. In parentheses is the number of injections. 
The differences in angiogeneic capabi lity between scleroderma and 
control lymp hocytes a re significant at p < 0.05, as estimated by non-
parametric Kruskall -Wallis test. No signi ficant differences b~t.wee n 
diffuse scleroderma and CREST syndrome. 
T here was no s igni fica nt correlation between t he intensity 
of an giogeneic reaction evo ked by patients' lymphocytes and 
t he cl inica l a nd laborato ry parameters such as ANA t iter, 
hypergammaglobulinemia, extent of organ in volvement, a nd 
others. Stud ies on C MI revea led n o s ignifica nt corre lation 
between a ngioge neic capabili ty a nd DNCB reactivity. However, 
111 some cases of diffuse scleroderm a, t he assoc iation of low 
numbers o f E rosette- formin g cells a nd decreased reactivity of 
PHA corresponded to a dec rease in angiogeneic capability. 
Morphologic studies on semi t hin sections revea led high num -
bers of blood vessel profiles seen in t he proxmity of infil t rates 
t hat had bee n made by t he cell injections. The infiltration 
cons isted ma inly of lymphocytes a nd polymorphonuclear leu -
kocyte . Increased numbers of mast cells were frequ ent ly found 
at the s ite of a ngiogeneic reaction. The endotheli a l cells were, 
in t he majori ty of vessels, enla rged and bu lged into t he vessel 
lume n . On a utoradiograms t he labe led endothelial cell s a nd 
pericytes were found. The labeling of infil t rating cell s was 
p ronounced. 
DISCUSSION 
The resul ts showed that PBL from systemic sc le roderma 
patients di splayed a lowered capabi li ty to evo ke a ngiogenesi s 
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compared with lymphocytes from con t ro l individuals . There 
were no significant differences in a ngioge neic capabili ty be-
twee n lymphocytes from diffuse scle roderma and from CREST 
syndrome. The lowe red capability to evoke a ngioge nesis reflects 
a decrease in CMI (25]. S uch decrease was frequently observed 
in scleroderma patients [1 4,15] but its relations hip to an im-
ba la nce of helper/suppressor ratios [16-18,32], T -celllympho-
penia [15,33,34], t he existence of suppressive factor [14], or 
even t he presence of immune complexes [35,36], which may be 
indirectly immunosuppressive, is not fully elucidated. Also t he 
exact nature of t he effector cell in an a ngiogenesis assay is not 
known . 
Both huma n T a nd B cells were s hown to be capable of 
inducing angioge nesis in a xe nogen eic system [28], however , 
the former com poses t he major portion of PBL. Therefore, a ny 
functional a lteration within t he T -cell population would have 
a greater influence on t he overall PBL a ngiogenesis capability 
t han would proportional a lteration within t he B-cell popula-
tion . It was s hown th at inhibitory inte ractions occur among 
different T -cell subpopulation s when tested by the LIA assay 
[28]. Active rosette-forming cells and cells with moderate affin-
ity receptors fo r SRBC were shown to be highly angiogeneic 
when separated , but when mixed togethe r they displayed the 
same overall angioge neic potential as did a n unfractionated 
lymp hocyte population. The relation ofT-cell subpopulations 
isolated on . the basis of t he ir affi ni ty for S RBC to T helpers 
a nd T suppressors, defined with t he use of OTK 4 and OTK 8 
monoclonal a n t ibodies [37], is not yet fully kn own. 
In t he presen t study we observed a n ev ident decrease in 
an giogeneic capabili ty of lymp hocytes originating from un-
treated patients with systemic scleroderma . S ince t here is a 
cell-dose dependence of a n giogeneic reaction intensity (see 
Table II), it is easy to calculate t hat nearly twice as many cells 
of t hese patients a re required to induce a n a ngiogenesis of a 
given in tens ity compared with t hat evoked by control lympho-
cytes. T he dependence of lymp hocyte a ngioge neic capability on 
the type and stage of systemic scleroderma a nd effects of 
therapy requires, howeve r, further studies. Also, t he exact na-
ture of e ffector ce ll s in a ngiogenesis assay with t he use of 
human PBL from systemic scleroderma patients remains to be 
dete rmined. However, t he lowered a ngiogeneic capabi li ty of 
scleroderma lymphocytes seems to be specific fo r t his disease. 
In our pre limina ry experimen ts we fo und t his capabi lity to be 
increased in systemic lupus erythematosus (mean 15.59) and in 
pso rias is vu lgaris (mean 15.56) [38 and in preparation]. 
T he question a rises as to what is the relation of the lowered 
a ngioge ne ic capability of lymphocytes to the pathomechanism 
of sc leroderma, i.e., whethe r it migh t be responsible for some 
of t he vascular chan ges . It is known t hat in normal conditions 
vascu lar endothe lium is a s lowly re newing cell population [39-
41]. Injury to endothelial cells by serum factors [20], cold (41], 
or other factors such as in fl ammatory cell s a nd t heir products 
will produce some loss of endothe lia l lining. Normally, t his is 
fol lowed by a rapid replacement of denuded a reas by new 
endothe li um during the process of proliferatio n , spreading, and 
migration. Ini t ia l regenerative processes might be ref1ected in 
an increased endothelia l labeling with tritiated t hymidine in 
capilla ries o f scleroderma sk in, found by Fleischmajer a nd 
Perl ish [ 42], a nd might not necessarily be re lated to the a ngi-
oge ne ic capabili ty. Angiogene ic factors t hat a ffect proliferation 
a nd migration of endothe lium [43] might play a role in t he 
repair of microdamage to the vessel lining. If t he mecha nisms 
respo ns ible for this production of a ngiogene ic factors are dis-
turbed, the repair of endothelium is delayed a nd t he exposure 
of subendothelium to blood prolonged. Damage to t he blood-
tissue barrier may be responsib le for t he increased penetration 
into t he extravascu lar space of some substances, i.e., serotonin 
and other tryptopha n metabolites [ 44 ] normally inactivated by 
endothelium [ 45 ] which, as a resul t, stimulate fibroblast prolif-
e ration [46]. 
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It was s hown that when t he angiogeneic stimulus is with-
drawn [47] t he capillaries undergo regression. Thus the capil-
la ry loss observed in scleroderma [21,22] might be explained 
at least partially, by a defect in lymphocyte a ngioge neic a bility: 
It is conce ivable t hat the a ngiogenesis tests may be useful in 
eva luatin g the vascu lar lesions of scleroderma and in the search 
for t he rapies preventing the lymphocyte angiogeneic defect. 
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